Emerging studies suggest Retatrutide , a dual agonist targeting both incretin and GIP , may offer a promising advancement for obesity management . Early clinical tests have shown substantial losses in visceral fat , possibly outperforming current obesity therapies . However , further study is necessary to fully assess its long-term impact and sa… Read More